Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07662096 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A First-In-Human Study of ARO-033 in Adult Participants

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Jul 18, 2027 → Jul 1, 2028
See other at-risk trials from Arrowhead Pharmaceuticals

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 18, 2027 to Jul 1, 2028 Show 4 more changesShow less
    • Enrollment increased: 42 → 84 participants
    • Trial arms changed: 2 → 4
    • Eligibility criteria expanded, about 161 words
    • Secondary endpoints revised (3)
  2. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 22, 2026 to Jun 25, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of ARO-033 compared to placebo in adult normal healthy volunteers (NHVs) and the safety, tolerability, PK, PD, and efficacy of multiple doses of ARO-033 in participants with age-related macular degeneration (AMD).
Trial Details
NCT Number NCT07662096
Lead Sponsor Arrowhead Pharmaceuticals
Conditions
(from sponsor)		 Age-related Macular Degeneration
Related terms Macular Degeneration
Enrollment 84 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov